TransCode Therapeutics (NASDAQ:RNAZ) Trading Down 1.5% – What’s Next?

TransCode Therapeutics Inc. (NASDAQ:RNAZ)’s stock price was down 1.5% during trading on Thursday . The company traded as low as $10.58 and last traded at $10.45. Approximately 10,110 shares were traded during trading, a decline of 12% from the average daily volume of 11,496 shares. The stock had previously closed at $10.61.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of TransCode Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 30th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $280.00.

TransCode Therapeutics Price Performance

The company’s fifty day moving average is $10.81 and its 200-day moving average is $10.46.

TransCode Therapeutics (NASDAQ:RNAZ) last issued its earnings results on Thursday, August 14th. The company reported ($4.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($8.68) by $3.74. As a group, analysts expect that TransCode Therapeutics Inc. will post -4.76 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TransCode Therapeutics stock. Warberg Asset Management LLC purchased a new position in TransCode Therapeutics Inc. (NASDAQ:RNAZ) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 50,000 shares of the company’s stock, valued at approximately $25,000. Warberg Asset Management LLC owned 0.21% of TransCode Therapeutics at the end of the most recent quarter.

About TransCode Therapeutics

TransCode Therapeutics, Inc, a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others.